100
Views
67
CrossRef citations to date
0
Altmetric
Research Article

In Vitro Antileishmanial Activity of Amphotericin B Loaded in Poly(ε-Caprolactone) Nanospheres

, , , , &
Pages 593-599 | Published online: 30 Sep 2008

  • Alvar, J., Caüavate, C, Gutierrez-Solar, B., Jimenez, M., Laguna, P., Lopez-Velez, R., Molina, R. and Moreno, J. (1997) "Leishmania and human immunodeficiency virus coinfection: the first 10 years", Clin. Micmbiol. Rev 10, 298-319.
  • Alving, C.R. (1988) "Macrophages as target for delivery of liposomes encapsulated antimicrobial agents". Adv. Drug Del. Rat. 2, 107-128.
  • Herman, J.D., Ksionski, G., Chapman, W.L., Waits, V.B. and Hanson, W.L. (1992) "Activity of amphotericin B cholesterol dispersion (Amphocil®) in experimental visceral leishmaniasis", Antimicrob. Agents Chemother. 36, 1978-1980.
  • Bolard, J., Joly, V. and Yeni, P. (1993) "Mechanism of action of amphotericin B at the cellular level. Its modulation by delivery systems", J. Liposome Res. 3, 409-427.
  • Caio Torres-Santos, E., Rodriguez, Jr., J.M., Moreira, D.L., Kaplan, M.A.C. and Rossi-Bergmann, B. (1999) "Improvement of in vitro and in vivo antileishmanial activities of 2',6'-dihydroxy-4'-methoxychalcone by entrapment in poly(D,L-lactide) nanoparticles", Antimicrob. Agents Chemother. 43, 1776-1778.
  • Cauchetier, E., Paul, M., Rivollet, D., Fessi, H., Astier, A. and Deniau, M. (2000) "Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of marine leishmaniasis". Int. J. Parasitai. 30, 777-783.
  • Croft, S.L., Davidson, R.N. and Thomton, E.A. (1991) "Uposomal amphotericin B in the treatment of visceral leishmaniasis", J. Antimicrob. Chemother. 28(B), 111-118.
  • Davidson, R.N., Croft, S.L., Scott, A., Main, M, Moody, A.H. and Bryceson, A.D.M. (1991) "Liposomal amphotericin B in drugresistant visceral leismaniasis", Clin. Infect. Dis. 22, 1-11.
  • Durand, R., Paul, M., Rivollet, D., Houin, R., Astier, A. and Deniau, M. (1997) "Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model". Int. J. Parasitai 27, 1361-1367.
  • Espuelas, M.S., Legrand, P., Irache, J.M., Gamazo, C, Orecchioni, A.M., Devissaguet, J.-Ph. and Ygartua, P. (1997) "Polyfe-caprolactone) nanospheres as an alternative way to reduce amphotericin B toxicity", Int. J. Pharm. 158, 19-279.
  • Espuelas, M.S., Legrand, P., Cheron, M., Barratt, G., Puisieux, P., Devissaguet, J-P. and Irache, J.M. (1998) 'Interaction of amphotericn B with polymeric colloids: 2. Effect of poloxamer 188 on the adsorption of amphotericin B onto poly (e-caprolactone) nanospheres". Colloids Surf. B11, 203-212.
  • Espuelas, S., Legrand, P., Loiseau, P.M., Bones, C., Barrat, G. and Irache, J.M. (2000) "In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188", Antimicrob. Agents Chemother. 44, 2190-2192.
  • Frezard, P., Michalick, M.S., Soares, CF. and Demicheli, C. (2000) "Novel methods for the encapsulation of meglumine antimoniate into liposomes", BFBZ. J. Med. Biol. Res. 33, 841-846.
  • Caspar, R., Preat, V, Opperdoes, RR. and Roland, M. (1992) "Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: activity against intracellular Leishmania donovani associated with hydrogen peroxide production", Pharm. Res. 9, 782-787.
  • Hammoda, N.A., Negm, A.Y., Hussein, E.D., el Temsahy, M.M. and Rashwan, E.A. (1996) "Leishmania major, leishmanicidal activity of activated macrophages by interferon gamma or tumour necrosis factor", J. Egypt Soc. Parasitai 26, 555-566.
  • Herwaldt, B.L. (1999) "Leishmaniasis", Lancet 354, 1191-1199.
  • Larabi, M, Legrand, P., Appel, M., Gil, S., Lepoivre, M., Devissaguet, J-R, Puiseaux, F. and Barratt, G. (2001) "Reduction of NO synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers", Antimicrob. Agents Chanother. 45, 553-562.
  • Legrand, P., Vertut-Doi, A. and Bolard, J. (1996) "Comparative intemalization and recycling of different amphotericin B formulations by a macrophage-like cell line", J. Antimicrob. Chemother. 37, 519-533.
  • Mbongo, N., Loiseau, P.M., Billion, M.A. and Robert-Gero, M. (1998) "Mechanism of amphotericin B resistance in Leishmania donovani promastigotes", Antimicrob. Agents Chemother. 42, 352-357.
  • Meyerhoff, A. (1999) "US Food and Drug administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis", Clin. Infect. Dis. 28, 49-51.
  • Mozaffarian, N., Berman, J.W. and Casadevall, A. (1997) "Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B", Antimicrob. Agents Chemother. 41, 1825-1829.
  • Müllen, A.B., Carter, K.C. and Bafflie, A.J. (1997) "Comparison of the efficacies of various formulations of amphotericin B against marine visceral leishmaniasis", Antimicrob. Agents Chemother. 41, 2089-2092.
  • Murray, H.W. (1999) "Kala-azar as an AIDS related opportunistic infection". Aids Patient care STDS13, 459-465.
  • Newman, MJ., Actor, J.K., Balussuhramanian, M. and Jagannath, C. (1998) "Use of nonionic block copolymers in vaccines and therapeutics", CnY. Reu Ther. Drug Carrier Syst. 15, 89-142.
  • Paul, M., Durand, R., Fessi, H., Rivollet, D., Houin, R., Astier, A. and Deniau, M. (1997) "Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a mutine model", Antimicrob. Agents Chemother. 41, 1731-1734.
  • Pearson, R.D. and Sousa, A.D. (1996) "Clinical spectrum of Leishmaniasis", Clin. Infect. Dis. 22, 1-11.
  • Rodriguez, J.M., Croft, S.L., Fessi, H., Bories, C. and Devissaguet, J.-P. (1994) "The activity and ultrastnictural localization of primaquineloaded poly (D,L-lactide) nanoparticles in Leishmania donovani infected mice". Trop. Med. Parasitai 45, 223-228.
  • Sereno, D., Holzmuller, P. and Lemesre, J.L. (2000) "Efficacy of second line drugs on antimonyl-resistant amastigotes of Leishmania infantum", Acta Tropica, 25-31.
  • Vernier-Julienne, M.C., Vouldoukis, I., Monjour, L. and Benoit, J.P. (1995) "In vitro study of me anti-leishmanial activity of biodegradable nanoparticles", J Drug Targeting 3, 23-29.
  • Yardley, V. and Croft, S.L. (1997) "Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis", Antimicrob. Agents Chemother. 41, 752-756.
  • Yardley, V. and Croft, S.L. (2000) "A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis". Int. J. Antimicrob. Agents 13, 243-248.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.